Morristown Medical Center
Morristown Medical Center
News Article | May 16, 2017
SALT LAKE CITY--(BUSINESS WIRE)--Atlantic Health System, a leading non-profit, clinically integrated health care system in New Jersey, will use Central Logic’s technology solution to support the Comprehensive Care for Joint Replacement (CJR) bundled payments program implemented by the Centers for Medicare & Medicaid Services. Central Logic collaborated with Atlantic Health System to develop Central Logic Patient Connect™, the first web-based technology to operationalize care coordination. The software will organize data for patients as they transition from hospital care and ensure that follow-up care is delivered. “The relationship between Central Logic and Atlantic Health System is based on a shared mission of improving patient care,” said Jennifer Holmes, Central Logic CEO and President. “Atlantic Health System will be able to use our technology solution, Patient Connect™, for patients undergoing knee and hip replacements and expand the scope of follow-up care to reduce the likelihood that these patients will need to be readmitted to the hospital. When combined with our Transfer Center solution, Atlantic Health System will have information on the entire episode of care and provide valuable data from inside and outside of the hospital’s four walls. We are proud to collaborate with Atlantic Health System on this innovative effort.” Atlantic Health System was instrumental in the development of a CJR module for Central Logic Patient Connect™. Using the technology solution will allow Atlantic Health System to track both preoperative and postoperative patients and make better predictions once those patients are discharged. In November 2015, CMS enacted The Comprehensive Care for Joint Replacement (CJR) model, designed to reduce cost and promote better patient outcomes though streamlined coordination of care for Medicare patients receiving hip and knee replacement surgery. Atlantic Health System has been participating in this bundling initiative since its inception in April, 2016. “Our promise to our communities is that all who enter our system will receive the highest quality care delivered at the right time, at the right place, and at the right cost,” said Jim Smith, administrator of bundle payment models for Atlantic Health System. “We have had the strategy and structure in place. With Central Logic Patient Connect™, we now have the technology to more efficiently fulfill our commitment. Central Logic Patient Connect is a robust technology solution and implementing it at Atlantic Health System will not only increase the productivity and capability of our staff, but it will help to ensure quality of care and reduce readmissions, among other benefits.” “We ultimately want patients to be placed back in their homes and then provide those patients with the resources to be comfortable and recuperating successfully. I believe our system and Central Logic Patient Connect™ will help us meet this goal.” Additionally, utilizing Central Logic Patient Connect™ will help Atlantic Health System streamline how patients move through the continuum of care to improve outcomes including reduced lengths of stay and readmissions as well as better overall patient experiences. Central Logic Patient Connect™ also will create operational efficiencies and allow the system’s care navigators to oversee a larger population of patients while maintaining and improving the quality of patient care. Atlantic Health System and Central Logic continue to work closely to determine the next use cases for Patient Connect About Central Logic: Central Logic is a leading innovative healthcare software solutions company that offers a comprehensive “end to end” suite of solutions that captures key patient information from inside and outside the hospital’s four walls to provide real-time visibility throughout a patient’s care continuum journey. Its flagship innovation, Central Logic Patient Connect™, was launched in 2016 and is one in Central Logic’s “end to end” suite of software solutions that connects, captures, and reports on critical patient care issues. Founded in 2005, Central Logic works collaboratively with more than 500 hospitals and thousands of healthcare professionals – including physicians, administrators and healthcare staff – to help hospitals and systems standardize processes, centralize actionable data and operationalize care coordination. Atlantic Health System, headquartered in Morristown, New Jersey, is a leading non-profit, clinically integrated health care system comprised of Atlantic Medical Group with more than 900 physicians and multispecialty care providers, medical centers, rehabilitation and urgent care. Atlantic Medical Group had more than 1.2 million patient visits in 2016. Locations include Morristown Medical Center in Morristown, NJ; Overlook Medical Center in Summit, NJ; Newton Medical Center in Newton, NJ; Chilton Medical Center in Pompton Plains, NJ; Hackettstown Medical Center in Hackettstown, NJ; and Goryeb Children’s Hospital in Morristown, NJ, as well as Atlantic Rehabilitation Institute, and Atlantic Home Care and Hospice. It also includes its subsidiary, Atlantic Ambulance Corporation. Atlantic Health System comprises 1,747 licensed beds, nearly 16,000 employees and more than 3,700 physicians. Atlantic Health System has a medical school affiliation with the Sidney Kimmel Medical College at Thomas Jefferson University; is part of Atlantic Accountable Care Organization, one of the largest ACOs in the nation, and is a member of AllSpire Health Partners.
News Article | May 23, 2017
Guadagno is New Jersey's first ever Lieutenant Governor, an office she has held since 2009. She also serves as the state's Secretary of State. Prior to being elected to her first statewide office, Guadagno served as a former Assistant United States Attorney for the Eastern District of New York and the District of New Jersey. She was also deputy chief of the United State Attorney's Office's corruption unit from 1994-1998. During her tenure there, she brought successful prosecutions against both Republicans and Democrats. Maoli states, "As a candidate for governor, Guadagno understands what is needed in New Jersey for business and the people of this state, and she clearly has her priorities in order." She has called for cuts in property taxes and has promised to veto any tax increases. She notably fought Governor Christie's decision to raise the gasoline tax by 23 cents a gallon last year. She has also called for a property tax "circuit breaker," which will impose a five percent ceiling on the school portion of New Jersey homeowners' property taxes. She has also promised to renegotiate the state's pension and health benefits to ensure that state workers receive pensions that are equivalent to the private sector. "Kim is the real deal and the best choice for this job. I'm sure when the people of New Jersey get to know her, they'll see cares about the people of New Jersey, families, and she is beholden to no one but the tax payers. Most important, she is the best answer to the state's economic health and future." In addition to his automotive empire, which includes Whippany based Lexus of Route 10, Alfa Romeo of Morris County, Maserati of Morris County, plus BMW Springfield, Maserati of Bergen County, and Mercedes Benz of Goldens Bridge, New York, Maoli also has major real estate holdings in the state. He is recognized as a philanthropist, most recently, donating his Alnwick Hall abbey to the Women's Association for Morristown Medical Center to be this year's host estate for its "Mansions in May" fundraiser. He also recently sponsored Tony winner Melba Moore's appearance at Montclair State University to headline its annual benefit concert for Autism New Jersey. Maoli's involvement in politics is not new. In 2009, he was a member of the Executive Finance Committee for the New Jersey Governor Chris Christie. In 2015, he was named to Governor Chris Christie's Presidential Leadership team, and, last year he joined then candidate "Donald Trump for President" presidential run and then transition fundraising. Following that, Maoli served on the president's transition team. Now that his enterprises have expanded to New York, Maoli also recently endorsed Richard "Bo" Dietl, who is running for Mayor of New York. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-jersey-business-leader-tom-maoli-supports-kim-guadagno-300462725.html
News Article | June 29, 2017
Drs. Edward Romano, Matthew Vaccaro, and Robert Bizzarro offer patients an informative, user-friendly look into the comprehensive dental treatments offered at their Morristown practice by revealing their state-of-the-art website MORRISTOWN, NJ--(Marketwired - Jun 29, 2017) - The renowned general, restorative, and cosmetic dentists at Aesthetic Smiles of New Jersey recently collaborated with the team at Rosemont Media -- a San Diego-based digital marketing firm -- to provide patients with an all-encompassing informational resource detailing the range of oral health services offered at their Morristown practice. Together, they modernized Aesthetic Smiles' online presence with a sleek website design that showcases custom-built features, allows for easy navigation, and enhances the overall patient experience. Aesthetic Smiles of New Jersey has worked with Rosemont Media for a number of years and recently unveiled their second generation website. The new design boasts a one-of-a-kind navigation menu that functions like an opening door, inviting current and prospective patients into the practice's refreshed, welcoming setting. Detailed information on dental procedures -- both common and unique -- are exhibited on a range of exciting multimedia features. Additionally, patients can now access comprehensive material on many different treatments, including porcelain veneers, Invisalign®, sleep apnea, and TMJ disorder. In this way, the website communicates a bevy of new information, not only pertaining to the range of routine, aesthetic, and restorative services offered by the practice, but also relevant to the maintenance of exceptional oral health and general wellness. The fully responsive site utilizes smart navigation and is displayed beautifully across a plethora of platforms, including phones, tablets, laptops, and desktop computers. This accessibility ensures an enriching user experience on any device, regardless of screen size. Patients seeking additional information now have new, interactive ways to learn about their treatment options with features such as a before-and-after photo slider, comprehensive photo gallery, detailed procedural videos, and relevant informational blogs that are updated consistently. Up-to-date patient reviews and practice ratings gathered across all major platforms (including Facebook, Google+, and Yelp) can also be found in one location. This ease of access allows individuals to make a more informed decision about their treatment choices without sacrificing time or convenience. Drs. Romano, Vaccaro, and Bizzarro also sought to extend their online visibility, a feat that was achieved by incorporating the latest best practices in search engine optimization and content marketing. Combined, these advanced strategies ensure the site is appearing prominently on all major search engines so a variety of audiences are able to reach the practice's unique content. Ultimately, the functional design and digital marketing strategies implemented into the new website allow the practice to better connect with current and prospective patients, while providing individuals with vital information to enhance their oral health. Dr. Edward Romano is a 20-year sustaining member of the American Academy of Cosmetic Dentistry, and formerly served as a President of the organization's New Jersey chapter. He is currently in private practice, and maintains membership in the American Dental Association and the American Academy of General Dentistry, among many other affiliations. Dr. Romano holds the title of Dental Ambassador at Dawson Academy and has been featured on a number of media outlets, including CNN, CNN International, MSNBC, WPIX, and the Better Homes and Gardens Network for his proficiency in laser dentistry and other advanced dental techniques. Dr. Romano is available for interview upon request. Dr. Matthew Vaccaro is a member of the American Academy for Cosmetic Dentistry, American Dental Association, Academy of General Dentistry, and Tri-County Dental Society. During his time at the State University of New York in Buffalo, Dr. Vaccaro was the recipient of awards in dental implant placement and prosthodontics. He is also a graduate of Dawson Academy and the Rosenthal Institute for Aesthetic Dentistry. In addition to being in private practice, Dr. Vaccaro is currently on staff at the Morristown Medical Center, where he provides instruction in many aspects of dentistry, including cosmetic treatments and CEREC® techniques. Dr. Vaccaro is available for interview upon request. Dr. Robert Bizzarro is a graduate of the New Jersey Dental School and belongs to a number of professional dental organizations, including the Academy of General Dentistry, American Dental Association, NJ Dental Association, and Tri-County Dental Association, among others. Dr. Bizzarro completed his general practice residency at Morristown Medical Center under the mentorship of Drs. Edward Romano and Matthew Vaccaro, and now serves as an attending doctor at the facility's General Residency program in addition to his work at Aesthetic Smiles of New Jersey. Dr. Bizzarro is available for interview upon request. For more information, please visit aestheticsmilesofnj.com or facebook.com/AestheticSmilesOfNJ.
News Article | June 1, 2017
Dr. Alistar comes to Atlantic Health System from the Wake Forest School of Medicine, where she led the GI oncology team, bringing cutting-edge treatments to patients. While there, she designed, secured funding for and conducted five investigator-initiated therapeutic clinical trials. At Wake Forest University she was the Principal Investigator of the Precision Oncology study that is poised to generate new hypotheses in the era of genomic driven clinical trials. "When evaluating the best programs across the country to continue my work, I chose Atlantic Health System due to its leaders' strong commitment to innovation, clinical research and patient-centered care and bringing the latest treatments to cancer patients," said Dr. Alistar. "I look forward to expanding treatment options for patients with pancreatic cancer and other GI malignancies, and to working in a multidisciplinary fashion with my new colleagues at Atlantic Health System Cancer Care to improve treatment outcomes and develop new standards of care." Study of Pancreatic Cancer Drug Provides Hope for Difficult-to-Treat Patients In the new Lancet Oncology study, Dr. Alistar and colleagues conducted a Phase I clinical trial of CPI-613, in combination with a modified version of FOLFIRINOX, a current multidrug treatment regimen approved by the FDA for use in pancreatic cancer that has spread beyond the pancreas. The trial was designed to determine the maximum tolerated dose of CPI-613 when used in combination with the modified FOLFIRINOX regimen in patients with Stage IV pancreatic cancer. The study provided preliminary evidence of the drug combination's efficacy, as well as demonstrating its safety and tolerability. "This study gives me reason for hope," said Dr. Alistar. "Patients with metastatic pancreatic cancer have a dismal prognosis, and the toxicity of current therapies limits their usefulness, underscoring the desperate need for safer, more effective treatments. That is why I have dedicated my career to helping find effective therapies for pancreatic and other difficult-to-treat GI cancers." Dr. Alistar will serve as the Co-Principal Investigator with Dr. Philip Philip of Karmanos Cancer Center on a planned multi-center Phase II/III study of CPI-613 in combination with modified FOLFIRINOX for metastatic pancreatic cancer. She has led four other clinical trials of CPI-613 for GI cancers, as well as studies of other novel oncology drugs, and research to determine disease processes and genetic factors in cancers of the gastrointestinal tract. CPI-613, developed by New Jersey-based Cornerstone Pharmaceuticals, is a new type of medication known as an altered energy metabolism directed (AEMD) drug. It is the first anticancer drug of its kind. It is designed to disrupt the altered energy production pathways in cancer cells by selectively targeting a process in cell multiplication and survival. Pancreatic cancer is the third leading cause of cancer-related death in the United States, with a five-year survival rate of just seven percent. Fifty-three percent of patients are diagnosed with advanced disease. Dr. Alistar's primary focus at Wake Forest School of Medicine was on immuno-oncology and its application in treatment of gastrointestinal cancers of the pancreas, colon, rectum, bile duct and esophagus, as well as in treating melanoma. Her clinical research projects involved active collaborative efforts with other medical departments, such as radiation oncology and surgical oncology, as well as genetics. An assistant professor of internal medicine at Wake Forest before joining Atlantic Health, she was also a member of the Translational Cancer Genomics Committee, the GI Tumor Board, Internal Medicine Grand Rounds Committee, and the Hepatobiliary Oncology Committee. She is a member of the American Society of Clinical Oncology, the American Society of Hospice and Palliative Care Medicine, and the American Society of Hematology, among many other professional societies. She also serves as a member and advisor to several other health care organizations. She is certified by the American Board of Internal Medicine, in both internal medicine and medical oncology. Dr. Alistar received her medical degree from University of Medicine and Pharmacy, Cluj Napoca, Romania, and conducted her internship and residency at Englewood Hospital and Medical Center, where she was chief resident. After her residency, she was a fellow in hematology and medical oncology at Mount Sinai School of Medicine, Tisch Cancer Institute. She currently serves as an ad hoc reviewer for JAMA and was recently the recipient of the Danny Danielson Translational Innovation Award for her dedication to clinical research. Dr. Alistar is a physician with Atlantic Hematology Oncology at the Carol G. Simon Cancer Center -Morristown Medical Center campus. Dr. Alistar can be reached at 973-971-7960. Dr. Alistar is affiliated with Atlantic Medical Group, and is a participating provider in the Atlantic Accountable Care Organization. About Atlantic Health System - Atlantic Health System, headquartered in Morristown, New Jersey, is a leading non-profit health care delivery system in New Jersey. Our network includes Morristown Medical Center in Morristown, NJ; Overlook Medical Center in Summit, NJ; Newton Medical Center in Newton, NJ; Chilton Medical Center in Pompton Plains, NJ; Hackettstown Medical Center in Hackettstown, NJ; and Goryeb Children's Hospital in Morristown, NJ, as well as Atlantic Rehabilitation, and Atlantic Home Care and Hospice. It also includes its subsidiary, Atlantic Ambulance Corporation. Atlantic Health System comprises 1,747 licensed beds, more than 14,000 employees and more than 4,000 physicians. Atlantic Health System has a medical school affiliation with the Sidney Kimmel Medical College at Thomas Jefferson University; is part of Atlantic Accountable Care Organization, one of the largest ACOs in the nation, and is a member of AllSpire Health Partners. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dr-angela-alistar-national-leader-in-gastrointestinal-cancer-research-joins-atlantic-health-system-cancer-care-as-medical-director-gi-medical-oncology-300467648.html
News Article | July 18, 2017
According to Farber, "It takes so much more than the will to win to be a successful entrepreneur. Passion, horsepower, and persistence go hand-in-hand. And, that fits Tom Maoli to a tee." Farber goes in depth with Maoli, who started his career in 1982 and built a solid, successful worldwide global company. Then, in 2011, with no automotive retailing experience, Maoli purchased his first dealership, Lexus of Route 10 in Whippany. In just six short years, he has added five more luxury dealerships to his Celebrity Motor Car brand. Maoli says the experience with Farber was "amazing, and I love what Farber is doing because when he started, no one knew what an entrepreneur was. Today, entrepreneurs are worldwide celebrities and are idolized, like Steve Jobs, Donald Trump and on and on. "Schools, such as Highpoint University in Highpoint North Carolina, actually have entrepreneurship as a college major. Today, there are so many people who want to be entrepreneurs, and they need mentoring," says Maoli, who added that "Mind Your Business" show allows viewers to get inside the heads of successful entrepreneurs to hear what it takes to be successful. Maoli's Celebrity Motor Car Company's six luxury brand dealerships, are located in the Metropolitan area -- one in New York -- Mercedes Benz of Goldens Bridge New York, and five in New Jersey -- Maserati of Morris County, Alfa Romeo of Morris County, BMW of Springfield, Maserati of Bergen County, and Lexus of Route 10, all of which have a well-earned reputation for elevating both the image and operational facets of his dealerships. Maoli adds, "There are more to come in the near future." Maoli is also a respected philanthropist. In May, Maoli donated one of his real estate holdings, Alnwick Hall (The Abbey) in Morristown, to be the showcase residence for the Women's Association for Morristown Medical Center's "Mansions in May" fundraiser. The estimated total of money raised will exceed $2 million. In April, Maoli sponsored Broadway star Melba Moore's appearance at Montclair State University's annual fundraiser for Autism New Jersey. The December 2016 edition of Town and County Magazine named Maoli to its list of "Wealthy Supporters who are funding Trump's Transition." In 2009, he was a member of the Executive Finance Committee for New Jersey Governor Chris Christie. In 2015, he was named to Governor Chris Christie's Presidential Leadership team, and last year he joined then candidate Donald Trump for President's fundraising team and then served on the Trump transition team. Maoli was also honored as the Morris County Columbus Day parade's Man of the Year. No stranger to good causes, Maoli is also a large supporter of the Morris County Community Food Bank and the Morris County Interfaith Food Pantry.
News Article | July 27, 2017
A new study published in the European Heart Journal outlines a different way for cardiologists to determine which patients with aortic stenosis (AS)—a narrowing of the aortic valve in the heart that keeps it from opening fully—are most likely to be alive one year after a heart valve replacement procedure. Dr. Philippe Genereux, an interventional cardiologist and Co-Director of the Structural Heart Program at the Gagnon Cardiovascular Institute at Atlantic Health System’s Morristown Medical Center, served as the paper’s primary (lead) author. Under current guidelines, cardiologists considering a heart valve replacement for patients with AS use cardiac imaging to assess the narrowing of the valve, valve function, co-morbidities (chronic conditions), and other risk factors as determined by a patient’s Society of Thoracic Surgeons (STS) risk calculator score. The new study suggests that classifying patients differently—with a stronger emphasis on the extent of cardiac damage before valve replacement— predicts which patients will survive one year later. The study—Staging Classification of Aortic Stenosis based on the Extent of Cardiac Damage—is similar to the staging classification used with patients with cancer, where a lower stage indicates less disease, and showed that for each stage of cardiac damage, the risk of death increased by about 45 percent. 1,661 patients from Edwards Lifesciences’ PARTNER (Placement of Aortic Transcatheter Valves) 2 trials were assessed and pooled into five staging (risk) categories based on the extent of heart damage as assessed by echocardiography before they underwent a valve replacement procedure. The extent of cardiac damage, more than the usual risk factors as measured by STS score and frailty, was independently associated with an increased risk of death after an aortic valve replacement. After one year, 4.4 percent of patients in Stage 0 (2), 9.2 percent of patients in Stage 1 (19), 14.4 percent of patients in Stage 2 (116), 21.3 percent of patients in Stage 3 (85), and 24.5 percent of patients in Stage 4 (33) had expired. “Cardiologists are constantly looking for direction in how to best choose and treat patients with aortic stenosis,” said Genereux. “While many times this means recommending a valve replacement, this study demonstrates that the extent and level of cardiac damage should be a critical deciding factor. We wanted to provide a simple and intuitive way to characterize the consequences of the disease and assess its impact on survival. With that information, thousands of patients undergoing valve replacement procedures each year could be better informed and more confident about their cardiologist’s decision.” The landmark paper comes on the heels of Morristown Medical Center’s announcement that it was the first hospital in the world to randomize a patient to the EARLY TAVR (Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients With AsYmptomatic Severe Aortic Stenosis) trial, for which Genereux serves as the trial’s principal (lead) investigator. The EARLY TAVR trial is sponsored by Edwards Lifesciences. The paper is available at http:// https://academic.oup.com/eurheartj/article/4002776/Staging-classification-of-aortic-stenosis-based-on, and can also be found through its doi number: 10.1093/eurheartj/ehx381. About Aortic Stenosis (AS) and Transcatheter Aortic Valve Replacement (TAVR) Aortic stenosis (AS), one of the most common and serious valve diseases, is a narrowing of the aortic valve opening, restricting blood flow from the left ventricle of the heart to the aorta. Symptoms of AS include shortness of breath, chest pain, pressure or tightness, palpitations, fainting and decreased physical activity. For patients considered intermediate or high risk for surgical aortic valve replacement (TAVR)—a procedure where the heart’s aortic valve is replaced through a catheter in the groin as compared to open-heart surgery, is an FDA-approved, minimally invasive procedure to replace an aortic valve that has narrowed and fails to properly open. About the Gagnon Cardiovascular Institute at Morristown Medical Center The Gagnon Cardiovascular Institute at Morristown Medical Center, part of Atlantic Health System, was the first hospital in New Jersey to offer TAVR, and treats more valve patients than any other hospital in New Jersey. For more information on our current trials for patients with aortic stenosis, heart failure, or cardiomyopathy, please visit http://www.atlantichealth.org/valveresearch, or call the Valve Center at Morristown Medical Center at (973) 971-7001. About Atlantic Health System Atlantic Health System, headquartered in Morristown, New Jersey, is a leading non-profit, clinically integrated health care system comprised of Atlantic Medical Group with more than 900 physicians and multispecialty care providers, medical centers, rehabilitation and urgent care. Atlantic Medical Group had more than 1.2 million patient visits in 2016. Atlantic Health System locations include Morristown Medical Center in Morristown, NJ; Overlook Medical Center in Summit, NJ; Newton Medical Center in Newton, NJ; Chilton Medical Center in Pompton Plains, NJ; Hackettstown Medical Center in Hackettstown, NJ; and Goryeb Children’s Hospital in Morristown, NJ, as well as Atlantic Rehabilitation Institute, and Atlantic Home Care and Hospice. It also includes its subsidiary, Atlantic Ambulance Corporation. Atlantic Health System comprises 1,747 licensed beds, nearly 16,000 employees and more than 3,700 physicians. Atlantic Health System has a medical school affiliation with the Sidney Kimmel Medical College at Thomas Jefferson University; is part of Atlantic Accountable Care Organization, one of the largest ACOs in the nation, and is a member of AllSpire Health Partners.
News Article | August 10, 2017
But, asks Abbey owner Tom Maoli, "What do I do with this incredible iconic mansion now that this fundraiser is over? I am hoping the town will work with me to allow me to develop the property into a financially viable project, but if not, the sad reality is that the Abbey may have to be dismantled off for agricultural salvage then torn down." Maoli adds, "It is no longer affordable to have the building sitting there paying the exorbitant taxes and costs to maintain the property." Maoli notes that at this point his plans for a townhouse complex have being reviewed by the Morris township zoning commission but does not yet have a green light from them. He does, however, have the paperwork sitting on the corner of his desk for a permit to demolish the Abbey and construct something else. Maoli has delayed a decision on demolition because of the Abbey had hosted the Women's Association for Morristown Medical Center's 18th Mansion in May Designer Show House and Gardens. Area designers and landscapers brought the mansion back to its opulent, turn of the 20th Century glory. "This fundraiser was something very important to me and the community," says Maoli. "The Morristown Medical Center has been a provider of superior health care to residents of Morris County for more than 100 years, but now that the event is over, I'm going to have to make some serious decisions about the Abbey's future." In a recent interview, Maoli stated other alternatives have been presented to him by potential renters, such as a religious group, which proposed a mosque with a day school, something for which the property is zoned and would eliminate Maoli's need to pay taxes on the property, since houses of worship are real-estate tax exempt. But Maoli feels this is not the best use for such an important iconic monument of grandeur in Morris County, a place he calls home. "It's amazing, everywhere I go in the USA, from Palm Beach, the Hamptons, Boston to Beverly Hills, you tell someone you're from New Jersey and they ask 'where?' You reply Morristown as a point of reference and somewhere in the conversation the Abbey comes up and they all know it." But Maoli ended the interview by leaving the door open, stating, "Let's see what happens before I make any decisions." Built in 1904, Alnwick Hall hasn't been a residential building for nearly 100 years since the death of Edward and Rosaline Meany, the original owners of the Abbey. In the subsequent years, the Abbey has served as a Lutheran church, a bank and, most recently, an office building. Maoli is set to begin a "Save the Abbey" campaign in an effort to convince the Morristown zoning board how much the community feels about the demolition of one of the area's most iconic and last remaining mansion on "Millionaire's Row," which dotted Madison Avenue 100 years ago. An email petition for "SAVE THE ABBEY " link on the Abbey's website (theabbeymorristown.com) will allow visitors to register their comments and cast a vote, either YES = Save the Abbey- or NO = Tear it Down. About Tom Maoli: Aside from being the owner of the Abbey, Maoli is also the owner of ROI Real-Estate and Owner and Dealer Principle of the Celebrity Motor Car Company, which consists of Whippany, New Jersey based Lexus of Route 10, Alfa Romeo and Maserati of Route 10, BMW of Springfield, Maserati of Bergen County, and Goldens Bridge Mercedes-Benz of Westchester County, New York. Mr. Maoli is available for interviews about the status of the Abbey upon request
News Article | August 9, 2017
The Mastership Award is the highest honor available in the AGD and one of the most respected designations in the profession. This accomplishment meets the highest criteria for professional excellence. To accomplish this, Dr. Rangel completed more than 1,100 hours of continuing dental education in the 16 disciplines of dentistry, including 400 hours dedicated to hands-on skills and techniques. As a recipient of this award, Dr. Rangel has joined over 2208 members of the dental community who understand that great smiles and good oral health for their patients are the result of going above and beyond basic requirements. "The AGD is proud to honor Dr. Rangel for her commitment to continuing education and dedication to providing her patients with advanced and exceptional oral health care," says AGD President, Maria Smith, DMD, MAGD. "Dr. Rangel has gone above and beyond her duties, distinguishing herself professionally amongst her peers and exemplifying her allegiance to the dental community." Dr. Rangel graduated from the University of Pennsylvania School of Dental Medicine in 2000 and currently practices dentistry in Morristown, NJ. In addition to the AGD, Dr. Rangel is a member of the American Dental Association, and the NJ Dental Association. She is a staff member at Morristown Medical Center where she teaches and trains the dental residents. She has also provided dental care to underserved populations around the world with Healing the Children, NE and the Open Wide Foundation. Dr. Rangel is married to Mark Kontny and has one daughter, Skylar. The AGD is a professional association of more than 40,000 general dentists dedicated to staying up-to-date in the profession through continuing education. Founded in 1952, the AGD has grown to become the world's second largest dental association, which is the only association that exclusively represents the needs and interests of general dentists. More than 786,000 persons are employed directly in the dental industry. A general dentist is the primary care provider for patients of all ages and is responsible for the diagnosis, treatment, management and overall coordination of services related to patients' oral health needs. About the Academy of General Dentistry The Academy of General Dentistry (AGD) is a professional association of more than 40,000 general dentists, dedicated to providing quality dental care and oral health education to the public. Founded in 1952, AGD is the second largest dental association in the United State, and serves the needs and represents the interests of general dentists. For more information about the AGD, visit, www.agd.org. For more information about the AGD, please visit www.agd.org.
Slomovitz B.M.,Morristown Medical Center |
Slomovitz B.M.,University of Houston |
Coleman R.L.,University of Houston
Clinical Cancer Research | Year: 2012
Endometrial cancer is the most common gynecologic malignancy in the United States. Overactivation of the PI3K/AKT/mTOR pathway, a signaling pathway that plays an important role in cellular growth and survival, has recently been implicated in endometrial cancer pathogenesis, and as such, inhibition of the PI3K/AKT/mTOR pathway is of therapeutic interest. Preclinical and clinical studies are proving useful in elucidating the antitumor effects of different PI3K/AKT/mTOR pathway inhibitors, and in defining which patient populations these inhibitors might be most effective in. For example, an increasing amount of preclinical data suggest that loss of PTEN or genetic alteration of PIK3CA may be indicators of sensitivity to PI3K/AKT/mTOR pathway inhibition, while activating KRAS mutations may predict resistance. In the latter case, combined inhibition of the RAS/RAF/MEK and PI3K/AKT/mTOR pathways has been suggested as a therapeutic strategy. In addition, the PI3K/AKT/mTOR pathway has been implicated in conferring resistance to conventional therapies, and so PI3K/AKT/mTOR pathway inhibitors in combination with hormonal and/or cytotoxic agents are being evaluated. In conclusion, preclinical models are providing insights into the antitumor activity of PI3K/AKT/mTOR pathway inhibition, and are helping define patient populations most likely to benefit from these therapies. Clinical validation of these findings is ongoing. ©2012 AACR.
Fiel S.B.,Morristown Medical Center
Expert Review of Respiratory Medicine | Year: 2014
Inhaled antibiotic therapy, targeting Pseudomonas aeruginosa, is a fundamental component of cystic fibrosis (CF) management. Tobramycin inhalation solution (TIS) was approved in the United States (US) in 1998. Subsequent research efforts focused on developing products with a reduced treatment time burden. Aztreonam for inhalation solution (AZLI), administered via a more efficient nebulizer than TIS, was approved in the US in 2010. Dry powder for inhalation (DPI) formulations provide alternatives to nebulized therapy: tobramycin powder for inhalation (also known as TIP™) was approved in the US in 2013, and colistimethate sodium DPI received European approval in 2012. Other aerosolized antibiotics and regimens combining inhaled antibiotics are in development. Inhaled antibiotic rotation (e.g., TIS alternating with AZLI) is an important concept being actively tested in CF. © Informa Uk, Ltd.